NasdaqGS:RGENLife Sciences
Repligen (RGEN) Profitability Turnaround Tests Bullish High P/E Narrative
Repligen (RGEN) opened 2026 with Q1 results that follow a year in which quarterly revenue ranged from about US$154.9 million to US$197.9 million and basic EPS moved between US$0.10 and US$0.27. Over that stretch, the company has seen revenue progress from US$154.9 million in Q3 2024 to US$197.9 million in Q4 2025, while basic EPS shifted from a loss of US$0.01 per share to a profit of US$0.24 per share, signaling a clear move back into positive territory. For investors, that pattern of...